Concord Biotech Limited has informed the Exchange that Board of Directors at its meeting held on May 29, 2026, recommended Final Dividend of Rs. 7.55 per equity share.
CONCORDBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Concord Biotech's Board recommended a final dividend of Rs. 7.55 per equity share (face value Rs. 1) for FY 2025-26, subject to shareholder approval at the ensuing AGM. The record date is fixed for July 24, 2026. For the financial year ended March 2026, standalone revenue from operations declined to Rs. 1,05,507 lakhs from Rs. 1,20,009 lakhs in the previous year. Profit after tax stood at Rs. 26,327 lakhs compared to Rs. 37,296 lakhs in FY 2025. The Board also appointed Mrs. Ekta Gupta as Additional Independent Director and approved new internal and cost auditors for FY 2026-27. The company acquired Celliimune Biotech Private Limited as a wholly-owned subsidiary effective April 2, 2026.
The 29% decline in profit after tax reflects lower revenue, but the dividend recommendation signals management's confidence. The substantial Rs. 7.55 per share dividend is positive for income-focused investors.